Table 2 General characteristics of general practitioner (GP) evaluators of abstracts of randomized controlled trials of pharmaceutical treatments
GP characteristics | All GPs number = 354 | Abstracts with no mention of funding source or CoI number = 118 | Abstracts reporting funding source only number = 118 | Abstracts reporting funding source and CoI number = 118 |
|---|---|---|---|---|
Gender (male) - number (%) | 227 (64.9) | 78 (66.7) | 76 (65.5) | 73 (62.4) |
Age, years - median (Q1 to Q3) | 51.4 (36.4; 57.3) | 48.7 (37.1; 56.3) | 51.8 (36.2; 57.6) | 52.7 (37.4; 57.2) |
Receive fees from pharmaceutical industry - number (%) | 75 (21.6) | 30 (26.3) | 20 (17.1) | 25 (21.6) |
For performing a presentation | 22 (6.3) | 8 (7.0) | 7 (6.0) | 7 (6.0) |
For consulting | 16 (4.6) | 4 (3.5) | 6 (5.1) | 6 (5.2) |
For enrolling patients in a trial | 60 (17.3) | 26 (22.8) | 18 (15.4) | 16 (13.8) |
Participate (current or past) in a trial funded by pharmaceutical industry – number (%) | 151 (43.5) | 54 (47.4) | 47 (40.2) | 50 (43.1) |
Receive visits from medical representatives of pharmaceutical industry - number (%) | ||||
None | 174 (50.1) | 56 (49.1) | 59 (50.4) | 59 (50.9) |
1 to 5 per month | 84 (24.2) | 30 (26.3) | 25 (21.4) | 29 (25.0) |
6 to 10 per month | 54 (15.6) | 17 (14.9) | 21 (17.9) | 16 (13.8) |
>10 per month | 35 (10.1) | 11 (9.6) | 12 (10.3) | 12 (10.3) |